Net Loss Widens to $166.3M for ArriVent BioPharma in 2025, EPS $(4.32) on Higher R&D
AVBP sits 60% above its 52-week low of $15.47.
Summary
ArriVent BioPharma reported a significant net loss of $166.3 million for the year ended December 31, 2025, translating to an EPS of $(4.32), as detailed in its 10-K filing. This represents a substantial widening from the $80.5 million net loss reported in 2024, primarily driven by increased research and development and general and administrative expenses. While the company highlighted progress in its clinical programs and stated an expected cash runway of at least 12 months, the material increase in losses could raise concerns about future capital requirements and the pace of cash burn. Traders will closely watch the advancement of firmonertinib's Phase 3 trials and the company's ability to manage its expenses while progressing its pipeline.
At the time of this announcement, AVBP was trading at $24.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1B. The 52-week trading range was $15.47 to $27.22. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.